Immunic (IMUX) Operating Leases (2019 - 2026)

Immunic has disclosed Operating Leases across 8 years of filings, most recently posting $421000.0 for Q1 2026.

• Operating Leases for Q1 2026 came in at $421000.0, down 56.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $421000.0 (down 56.82% YoY), and the FY2025 annual result was $107000.0, down 59.47% from the prior year.
• Operating Leases came in at $421000.0 for Q1 2026 at Immunic, up from $107000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.0 million in Q1 2023 to a low of $107000.0 in Q4 2025.
• The 5-year median for Operating Leases is $502000.0 (2022), against an average of $674882.4.
• Across the five-year window, Operating Leases jumped 298.61% in 2023 and plunged 80.15% in 2024, its largest moves.
• Immunic's Operating Leases stood at $992000.0 in 2022, then plunged by 35.58% to $639000.0 in 2023, then sank by 58.69% to $264000.0 in 2024, then plunged by 59.47% to $107000.0 in 2025, then surged by 293.46% to $421000.0 in 2026.
• The last three Operating Leases figures came in at $421000.0 (Q1 2026), $107000.0 (Q4 2025), and $126000.0 (Q3 2025), per Business Quant data.